Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

The 58-year-old Danish executive has spent his entire career at Novo Nordisk, which he joined 34 years ago. Ozempic, which accounts for 41 percent of Novo Nordisk’s sales, is an injectable ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...

The U.S. Food and Drug Administration (FDA) and drug manufacturer Novo Nordisk are warning consumers about “counterfeit” Ozempic found outside the authorized drug supply chain. The contents of ...

Novo Nordisk (NVO) said it has become aware of several hundred units of Ozempic injection outside the Novo Nordisk authorized supply chain in the U.S. The US Food and Drug Administration has also ...

Novo Nordisk (NVO) has become aware of several hundred units of Ozempic injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the U.S., the company announced.

April 14 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its authorized supply chain ...

The Ozempic shortage is over and the Ozempic era is here. Novo Nordisk launched its latest campaign – My Ozempic Era – just a few weeks after the Food and Drug Administration took semaglutide, the ...

PLAINSBORO, N.J., March 3, 2025 /PRNewswire/ -- Novo Nordisk launched "My Ozempic ® Era" today, a national campaign which spotlights the longstanding Ozempic ® patient community by sharing ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks associated with chronic kidney disease (CKD). The Danish drugmaker’s popular ...

The Food and Drug Administration on Tuesday approved Novo Nordisk's Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular ...